BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231205
DTEND;VALUE=DATE:20231208
DTSTAMP:20260517T023516
CREATED:20230915T100043Z
LAST-MODIFIED:20230915T100043Z
UID:37804-1701734400-1701993599@www.pharmajournalist.com
SUMMARY:3rd ADC Target Selection Summit
DESCRIPTION:The 3rd ADC Target Selection Summit (December 5-7 | Boston\, MA). This is the ultimate cover-to-cover conference providing insights to help you optimize the pairing of target\, antibody\, and linker-payload and develop the next generation of clinically successful ADCs beyond HER2 and TROP2. \nSee the full program here. \nAs the number of new clinical ADC targets continues to increase\, this year’s meeting will have a greater focus on identifying and validating novel targets\, re-examining what makes a good target\, and delving into the use of proteomics to ensure you get the first step of drug development right. \nHere are some of the agenda highlights you cannot afford to miss: \n\nJoin Cancer Research Horizons to learn “Overcoming Hurdles in Validating Novel Targets for Clinically Applicable ADCs” and hear how an unbiased proteomics approach with patient samples was used to discover a clinically relevant ADC target for multiple myeloma\nHear from Ziel Bio on “Discovering Cell Surface Plectin: A Highly Promising Target for Multiple Solid Tumors” to understand how the hypothesized function of plectin highlights it as a good ADC target\, and learn how ZB131 can selectively bind to CSP improving internalization and minimizing off-target effects\nGain insights from AstraZeneca on “A Case Study on Utilizing Hindsight Following Progression of an ADC With a HER2 Target Into the Clinic” highlighting the target selection process and reasons behind the choice of pursuing HER2\, target and antibody considerations; and emphasizing challenges and successes in the use of this target for ADCs to help you prepare for your development.\n\nTake a look at the full speaker faculty and session details. \nUniting 100+ of your peers working in biology\, discovery and oncology research\, this unique forum will provide you with an exclusive opportunity to learn and network with other ADC developers who are living and breathing targets all in one room.
URL:http://www.pharmajournalist.com/event/3rd-adc-target-selection-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231205
DTEND;VALUE=DATE:20231208
DTSTAMP:20260517T023516
CREATED:20230920T102331Z
LAST-MODIFIED:20230920T102331Z
UID:37817-1701734400-1701993599@www.pharmajournalist.com
SUMMARY:3rd Applied Biocatalysis Summit
DESCRIPTION:Enzyme Engineering Enabling Scalable Industrial Biotransformation for Sustainable API Production \nIn 2023\, an era of advanced enzyme engineering technology is rapidly enabling the generation of game-changing enzymes for novel transformations. As witnessed for Merck’s Islatravir and BMS’ ERED/KRED biocatalytic cascade recognition\, industries are fast transitioning towards biocatalysis to capitalize on more sustainable means of synthesis. The 3rd Applied Biocatalysis Summit is your must-attend meeting dedicated to accelerating enzyme discovery and reaction route development\, through to scaling process chemistry for industrial applications. \nWith unmissable case studies from the likes of Merck\, Amgen\, Sanofi\, Biogen\, GSK\, and Pfizer\, this is the definitive forum to benchmark and learn with this forward-thinking community who reunite once more. \nThese industry titans have collaborated to form a comprehensive\, 3-day program covering key topics including: \n\nGaining valuable insights on chemoenzymatic catalysis research\, combining heterogeneous and homogeneous catalysis and making valued functionality using biocatalysis\, in water with Bruce Lipshutz\, Professor of Chemistry\, University of California\, Santa Barbara\nLearn how new technologies are adding efficiencies to biocatalysis’ adoption\, including AI/ML approaches\, improved screening for reaction prediction & new chemistry discoveries with Merck & Pfizer\nEngage in dynamic panel discussions addressing how cross-departmental collaboration enable the faster assessment and introduction of enzymatic catalysed reactions as early as possible with AbbVie\, Biogen & Neorocrine Biosciences\n\nDon’t miss this opportunity to join trailblazers and accelerate enzyme discovery and engineering\, discover carbon footprint-reducing reactions and refine your process scaling strategies.
URL:http://www.pharmajournalist.com/event/3rd-applied-biocatalysis-summit/
LOCATION:The Study at University City\, 20 S 33rd Street\, Philadelphia\, PA\, 19104\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231212
DTEND;VALUE=DATE:20231215
DTSTAMP:20260517T023516
CREATED:20230908T111459Z
LAST-MODIFIED:20230908T111459Z
UID:37759-1702339200-1702598399@www.pharmajournalist.com
SUMMARY:Covalent Drug Discovery Summit
DESCRIPTION:Bringing the covalency field under one roof for the first time\, the inaugural Covalent Drug Discovery Summit comes to Boston this December – gathering 80+ covalent drug specialists from the likes of Amgen\, Revolution Medicines\, Novartis\, Totus Medicines\, Covant Therapeutics and more. \nThis is a unique opportunity to network with an audience of CXOs\, VPs\, Directors and Heads of Discovery\, Medicinal and Biological Chemistry focused on covalent drug discovery. \nHear from 20+ industry leaders across three days of carefully curated content\, engage in dedicated networking time with the field\, ask your burning questions to our expert speakers at the end of each presentation\, and dive deep into two interactive workshops on toxicity and safety concerns and the future of covalency. \nDownload your copy of the program here to find out more: https://ter.li/z6hwj6
URL:http://www.pharmajournalist.com/event/covalent-drug-discovery-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231212
DTEND;VALUE=DATE:20231215
DTSTAMP:20260517T023516
CREATED:20230914T091348Z
LAST-MODIFIED:20230914T091348Z
UID:37788-1702339200-1702598399@www.pharmajournalist.com
SUMMARY:6th RNA-Targeted Drug Discovery & Development Summit
DESCRIPTION:200+ Attendees | 33+ World-Class Speakers | 23+ Data Driven Case Studies \nReturning to Boston this December for its 6th year\, the RNA-Targeted Drug Discovery & Development Summit is the only industry-dedicated forum solely focused on small molecules targeting RNA\, with a core focus on improving selectivity and specificity to enable safe and effective drugs into the clinic. \nView the program here: https://ter.li/xq2eye \n2023 has seen advances in artificial intelligence\, screening tools and progression into the clinic\, coupled with numerous strategic collaborations and investments into early discovery. \nBringing together 33+ experts presenting the latest data and case studies straight from the lab\, alongside senior decision makers discussing key breakthroughs and strategy\, this year’s meeting is a must-attend if you are looking to turbocharge discovery and development of small molecules targeting RNA. \nRegister here: https://ter.li/r67ejq
URL:http://www.pharmajournalist.com/event/6th-rna-targeted-drug-discovery-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231212
DTEND;VALUE=DATE:20231215
DTSTAMP:20260517T023516
CREATED:20231018T112219Z
LAST-MODIFIED:20231018T112219Z
UID:37976-1702339200-1702598399@www.pharmajournalist.com
SUMMARY:Health Economics & Outcomes Research Summit
DESCRIPTION:The Health Economics & Outcomes Research Summit is a focused intimate gathering of HEOR professionals\, moving past basic introductions to advanced tactical and strategic conversations best leveraging innovative methods to demonstrate the value proposition of new drugs to secure formulary and market access. \nHear cutting-edge case studies into evidence generation\, modeling and real-world evidence across oncology\, neurology\, cardiovascular\, rare diseases\, and beyond. Explore how leading pharma and pioneering biotechs are navigating this changing landscape including:  \n\nAdapting value assessments for evolving reimbursement requirements\nAdjusting to price control mechanisms implemented by the Inflation Reduction Act\nLeveraging advances AI to revolutionize data-driven decision-making \n\n\nJoin this gathering of HEOR experts and gain strategic and commercial market intelligence by exploring how thought leaders are redefining a robust strategy to demonstrate the clinical effectiveness\, safety\, and cost-effectiveness of new drugs\, don’t miss out on your opportunity to fortify a resilient decision-making framework.  \nTo know more visit: https://bit.ly/3PTp5M4
URL:http://www.pharmajournalist.com/event/health-economics-outcomes-research-summit/
LOCATION:Wyndham Philadelphia Historic District\, 400 Arch Street\, Philadelphia\, PA\, 19106\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231212
DTEND;VALUE=DATE:20231215
DTSTAMP:20260517T023516
CREATED:20231031T110228Z
LAST-MODIFIED:20231031T110322Z
UID:38052-1702339200-1702598399@www.pharmajournalist.com
SUMMARY:8th Oncolytic Virotherapy Summit 2023
DESCRIPTION:Following recent struggles in the industry\, the leading annual 8th Oncolytic Virotherapy Summit returns to Boston\, MA in December (12-14)\, as the industry’s definitive\, and most comprehensive forum. Bringing you 29+ world-class speakers\, 10+ hours of networking\, 2-panel discussions\, 1 pre-conference focus day & more. This event will be showcasing brand-new pivotal data to ensure a pathway of success for regulatory approval of OV drugs. \n3 days of carefully curated sessions will gather 100+ OV trailblazers across sessions spanning Early Discovery\, Translation\, Clinical Development\, Chemistry\, Manufacturing & Controls (CMC)\, and Regulations to overcome the industry’s largest and critical bottlenecks. Here is just a snapshot of our world-class speaker line-up who will be showcasing their expertise and critical updates: \n\nRichard Dambra\, Scientist\, Viral Platforms\, Boehringer Ingelheim\nFrancesca Barone\, CSO\, Candel Therapeutics\nMichael Franti\, Director\, Viral Platform Drug Metabolism & Pharmacokinetics\, Boehringer Ingelheim\nPaul Hallenbeck\, Chief Scientific Officer\, Seneca Therapeutics\nTalia Biran\, President Clinical Development Operations\, Oncolys\n\nThis year’s edition brings highly promising content such as the exclusive Innovation Showcase\, a whole day dedicated to Clinical Design & Manufacturing Strategies and a must-attend Investor Panel from experts in Biopharma. \nAs the only and longest established end-to-end OV-focused conference\, this is a crucial date in the industry calendar you cannot afford to miss. \nTo know more visit: https://ter.li/1ag3m6
URL:http://www.pharmajournalist.com/event/8th-oncolytic-virotherapy-summit-2023/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231213
DTEND;VALUE=DATE:20231215
DTSTAMP:20260517T023516
CREATED:20230907T095249Z
LAST-MODIFIED:20230907T095249Z
UID:37740-1702425600-1702598399@www.pharmajournalist.com
SUMMARY:Gene Therapy Process Development Summit
DESCRIPTION:The inaugural Gene Therapy Process Development Summit is a must-attend to discover the latest insights to bridge the gap between R&D and process development\, ensuring that high-quality gene therapies are manufactured repeatably\, at scale\, and in a cost-effective manner. \nJoin us in Philadelphia to discover and learn the latest insights through case study presentations\, informative panel discussions\, and deep-dive workshops from Ultragenyx\, REGENXBIO\, Janssen\, Amgen\, Astellas Gene Therapies\, and many more! \nWhether you are looking to improve your platform processes or shorten development timelines this summit will be a unique opportunity to meet and network with peers to discuss successes and challenges in your process development journeys. \nJoin your peers to: \n\nLearn how to achieve the ideal complex size with Meira GTx by using automation and process analytical tools to optimize transient transfection leading to enhanced efficiency\, time saving and scale-up insights\nDeep dive into enhancing the Pinnacle PCL Platform 2000L batch process with Ultragenyx to increase yield\, improve product quality and reduce time-to-clinic\nExamine case study results with Astellas Gene Therapies and explore the optimization techniques to cut costs and streamline tech transfer and scale-up times\nExplore the design principles for creating robust AAV producer cell lines to yield a stable and consistent AAV production to optimize AAV vector generation to improve your platform processes with Lacerta and REGENXBIO\nUnpick the ever-changing\, complex regulations surrounding the world of gene therapy in a detailed workshop that doubles down on development strategies that are adaptable to the challenges by gene therapy to prevent regulatory roadblocks when trying to get drugs to clinic\n\nDownload the full agenda here to see our full speaker faculty\, 2-day agenda and audience breakdown: https://ter.li/nxp0nz
URL:http://www.pharmajournalist.com/event/gene-therapy-process-development-summit/
LOCATION:Le Meridien Philadelphia\, 1421 Arch Street\, Philadelphia\, PA\, 19102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR